Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma

Roy E. Strowd, Benjamin M. Ellingson, Catalina Raymond, Jingwen Yao, Patrick Y. Wen, Manmeet S. Ahluwalia, Anna F. Piotrowski, Arati Desai, Jennifer Clarke, Frank S. Lieberman, Serena Desideri, Burt Nabors, Xiaobu Ye, Stuart A. Grossman